Clinical Trials Newswire

Live Results

1 - Penumbra Announces Worldwide Voluntary Field Removal of the Original Version of 6F Neuron 070 Delivery Catheter

ALAMEDA, Calif.-(Business Wire)-September 30, 2009 - Penumbra is initiating a voluntary Field Removal of the original version of Neuron 6F 070 Delivery Catheter. For these catheters, Penumbra has received feedback from some users that the catheter could kink or ovalize in certain anatomical...

2 - Idaho Technology Expands Its High Resolution Melting Patent Portfolio

SALT LAKE CITY-(Business Wire)-September 29, 2009 - Idaho Technology’s patent portfolio continues to grow as the U.S. Patent and Trademark Office granted the company U.S. Patent No. 7,582,429 relating to methods of performing genetic analysis in the presence of a double-stranded nucleic acid...

3 - Celera to Webcast Presentation at JMP Securities 2009 Healthcare Conference

ALAMEDA, Calif.-(Business Wire)-September 29, 2009 - Celera Corporation (NASDAQ:CRA) announced today that it will webcast its presentation at the JMP Securities 2009 Healthcare conference on Tuesday, October 6, 2009. The live webcast is scheduled to begin at 10:00 am ET. Ugo DeBlasi, Chief Financial...

4 - SeraCare Life Sciences Awarded Multiple Contracts from the CDC and NIH to Support HIV Research and the Accuracy of HIV Testing

MILFORD, Mass.-(Business Wire)-September 29, 2009 - SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced that the Company has been awarded two new contracts from the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) and that a third existing contract has been...

5 - New Clinical Data Shows AMS’ Minimally Invasive Treatment Options Effective at Restoring Female Pelvic Health

MINNETONKA, Minn.-(Business Wire)-September 29, 2009 - American Medical Systems® (AMS) (NASDAQ: AMMD), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of three major clinical studies that each point to a high degree of...

6 - ABL and Evivar Medical Enter into Agreements to Form a Global Strategic Partnership and IP Cross-Licensing for Disease Management and Personalized Healthcare of Hepatitis B and HIV Infections

LUXEMBOURG & MELBOURNE, Australia-(Business Wire)-September 29, 2009 - ABL, S.A. and Evivar Medical Pty Ltd today announced the completion of agreements to cross-licence their respective intellectual property portfolios and to form strategic alliances based on the use of their proprietary...

7 - LifeCycle Pharma Announces Positive Results from a 12 Month Extension Phase of the Phase 2 Clinical Study of LCP-Tacro™ Once Daily in Stable Liver Transplant Patients

HØRSHOLM, Denmark-(Business Wire)-September 29, 2009 - LifeCycle Pharma A/S (CSE:LCP) today announced positive results from a completed 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients. LCP-Tacro is a once daily immunosuppression drug...

8 - PolyMedix Initiates Dosing in Phase 1B Clinical Study of Novel Anticoagulant Antagonist Compound

RADNOR, Pa.-(Business Wire)-September 29, 2009 - PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a...

9 - ImThera Medical to Begin European Clinical Trials in Belgium

SAN DIEGO-(Business Wire)-September 29, 2009 - ImThera Medical, Inc. has received Ethics Committee clearance to begin human clinical trials in Belgium. The trials will include ImThera’s Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy to treat Obstructive Sleep Apnea (OSA). Along with the...

10 - Luminex Corporation Hosts Seventh Annual Planet xMAP Europe

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it will host Planet xMAP Europe 2009, its annual European multiplexing technology symposium, October 7-8, 2009, at Beurs van Berlage in Amsterdam. The program for Planet xMAP Europe 2009...

11 - Bio Japan 2009: The Biggest Biotechnology Event in Japan.

YOKOHAMA, Japan-(Business Wire)-September 29, 2009 - We would like to thank you sincerely for your understanding and ongoing cooperation for BioJapn. With your wholehearted support, BioJapan has been progressing successfully in both its contents and scale every year. This year, we are aiming to...

12 - Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma

BERKELEY, Calif.-(Business Wire)-September 29, 2009 - Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug...

13 - Sermo Panels Tap into Social Media Platform for On-Demand Physician Opinions

CAMBRIDGE, Mass.-(Business Wire)-September 29, 2009 - Sermo, the largest online community exclusively for physicians, today formally launched Sermo Panels™ - a new on-demand offering enabling businesses to engage with and gather insights from physicians in a private online workspace. Sermo Panels...

14 - SFC Fluidics, LLC Receives Funding from US Army for Development of Traumatic Brain Injury Diagnostic Device

FAYETTEVILLE, Ark.-(Business Wire)-September 29, 2009 - SFC Fluidics, LLC recently announced it has received a contract for approximately $5 million from the Congressionally Directed Medical Research Program for development of a handheld device for rapid diagnosis of traumatic brain injury (TBI...

15 - Cerus to Present Proposal for INTERCEPT Platelet US Phase III Clinical Trial at November BPAC Meeting

CONCORD, Calif.-(Business Wire)-September 29, 2009 - Cerus Corporation (NASDAQ:CERS) announced today that it will present the proposed design for a U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets at the upcoming November meeting of the FDA's Blood Products Advisory...

16 - BSD Medical Corporation Sells Hyperthermia System to University of California, San Francisco Medical Center

SALT LAKE CITY-(Business Wire)-September 29, 2009 - BSD Medical Corporation (NASDAQ: BSDM) (www.BSDMedical.com) announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia System (BSD-500). UCSF is a world leader in hyperthermia and...

17 - Computable Genomix Announces Contest For Genomics Researchers

MEMPHIS, Tenn.-(Business Wire)-September 29, 2009 - Memphis-based Computable Genomix today announced it will launch a contest on Oct. 1, 2009, to coincide with the release of GeneIndexer, the company’s next-generation Web-based text-mining tool. Publish or Perish will award a $10,000 grant to each...

18 - Synta Pharmaceuticals Initiates Fourth Trial of STA-9090, a Novel Synthetic Small Molecule Hsp90 Inhibitor

LEXINGTON, Mass.-(Business Wire)-September 29, 2009 - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical...

19 - pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien® Study

WATERTOWN, Mass.-(Business Wire)-September 29, 2009 - pSivida Corp (NASDAQ: PSDV)(ASX: PVA), a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today...

20 - Acrux Announces Successful AXIRON™ Phase III Trial Results

NEW YORK-(Business Wire)-September 29, 2009 - Australian company, Acrux, today announced positive results from a Phase III trial evaluating the safety and efficacy of AXIRON™ in 155 men with testosterone deficiency (hypogonadism), across 26 sites in six countries. AXIRON™ is applied to the...

21 - Aurora Breast MRI of Sarasota and Clear Channel Radio, Partner for “Change for Change” Fundraising Event

SARASOTA, Fla.-(Business Wire)-September 29, 2009 - Aurora Breast MRI of Sarasota today announced it has partnered with Clear Channel Radio for a fundraising effort to benefit The Wellness Community of Southwest Florida. The fundraiser, titled “Change for Change,” will consist of a series of...

22 - Spectranetics Submits 510(k) Application to Food and Drug Administration Seeking Clearance for the Treatment of In-Stent Restenosis in the Legs

COLORADO SPRINGS, Colo.-(Business Wire)-September 29, 2009 - Spectranetics Corporation (Nasdaq: SPNC) today announced that it has filed a 510(k) application with the Food and Drug Administration seeking clearance for the treatment of in-stent restenosis (ISR) in the legs with its commercially...

23 - Dynavax Initiates Phase 3 Registration Trial in Chronic Kidney Disease Patients for HEPLISAVTM Hepatitis B Vaccine

BERKELEY, Calif.-(Business Wire)-September 29, 2009 - Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot...

24 - Repros Therapeutics Inc. Provides Update on Proellex

THE WOODLANDS, Texas-(Business Wire)-September 29, 2009 - Repros Therapeutics (NasdaqGM:RPRX) today announced that the Company has received further clarification from the Food and Drug Administration (FDA) on the Full Clinical Hold status of Proellex. As announced in early August 2009, and after...

25 - PPD Announces Third Quarter 2009 Earnings Release, Webcast and Conference Call

WILMINGTON, N.C.-(Business Wire)-September 29, 2009 - PPD, Inc. (Nasdaq: PPDI) will release its third quarter 2009 financial results on Tuesday, October 27, 2009, after the market closes. The earnings release will be available on the PPD Web site at http://www.ppdi.com, FirstCall and Business...

26 - BioClinica™ Showcases Clinical Data Management at SCDM Annual Conference

NEWTOWN, Pa.-(Business Wire)-September 29, 2009 - BioClinica, Inc., (NASDAQ: BIOC) a leading global provider of clinical trial services, is helping to advance the discipline of clinical data management and will demonstrate integrated eClinical and imaging data management technology and expertise...

27 - Flexible Stenting Solutions, Inc. Receives Conditional IDE Approval for FlexStent® Femoropopliteal Self Expanding Stent System

EATONTOWN, N.J.-(Business Wire)-September 28, 2009 - Flexible Stenting Solutions Inc. (“FSS”), a leading developer of next generation peripheral arterial and biliary stents, announced today that it has received Conditional Investigational Device Exemption (IDE) approval for its FlexStent...

28 - Maxygen Announces Management Changes

REDWOOD CITY, Calif.-(Business Wire)-September 28, 2009 - Maxygen, Inc. (Nasdaq:MAXY) announced today that James Sulat, who currently serves as a director of the company, has been appointed to serve as Maxygen’s Chief Executive Officer, effective October 1, 2009. Mr. Sulat will replace Russell...

29 - Burzynski Research Institute Signs Research Agreement with the University of Alabama at Birmingham (UAB), Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility

HOUSTON-(Business Wire)-September 28, 2009 - The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management...

30 - International Medica Foundation Starts Phase II Clinical Trial for Rotavirus Vaccine

ROCHESTER, Minn.-(Business Wire)-September 28, 2009 - More than half a million children – or 1,400 to 1,600 each day – die from rotavirus, the most common cause of severe childhood diarrhea. Almost all of these deaths occur in developing countries, where lifesaving medical care may not be...

31 - DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs

BIRMINGHAM, Ala.-(Business Wire)-September 28, 2009 - DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of...

32 - Savvion and Patni Announce Strategic Partnership

SANTA CLARA, Calif.-(Business Wire)-September 28, 2009 - Savvion® and Patni Life Sciences announced today a strategic partnership to jointly deliver Business Process Management (BPM)-enabled solutions for clinical operations on top of Savvion’s Life Sciences Foundation. Savvion and Patni will...

33 - Biomagnetics Diagnostics Receives a Financing Commitment up to $1 Million to Speed Development of Malaria Testing Technology

GENEVA-(Business Wire)-September 28, 2009 - Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced it has received a equity-based financing commitment up to $1 million...

34 - Ligand and GlaxoSmithKline Collaboration Identifies New Compound

SAN DIEGO-(Business Wire)-September 28, 2009 - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline (NYSE:GSK), GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would...

35 - PolyMedix Receives U.S. Patent Protection for Licensed Computational Methods to Design Antimicrobial Polymers

RADNOR, Pa.-(Business Wire)-September 28, 2009 - PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has received patent protection for...

36 - Hythiam Announces First Peer-Reviewed Publication of Statistically Significant Results from Randomized, Double-Blind, Placebo-Controlled Study

LOS ANGELES-(Business Wire)-September 28, 2009 - Hythiam, Inc. (NASDAQ:HYTM) announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the...

37 - Helicos Announces System Sale to Correlagen Diagnostics

CAMBRIDGE, Mass.-(Business Wire)-September 28, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS) today announced the sale of a system and a scientific collaboration with Correlagen Diagnostics Inc., a leading provider of genetic tests for disease diagnosis. “We are very excited to have...

38 - Halozyme Begins Clinical Trial to Compare Three Insulin Analogs and Provides Update on Ultrafast Insulin Program

SAN DIEGO-(Business Wire)-September 28, 2009 - Halozyme Therapeutics, Inc. (Nasdaq:HALO) today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase...

39 - Life Technologies and febit Team to Offer New Solution for Targeted Re-sequencing in Large-scale Genomic Studies

CARLSBAD, Calif. & HEIDELBERG, Germany-(Business Wire)-September 28, 2009 - febit holding GmbH and Life Technologies Corporation (NASDAQ: LIFE) today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted...

40 - Thommen Medical Announces Chairside Implant Conditioning – North American Premiere at the 2009 AAOMS Meeting in Toronto, Canada

CLEVELAND-(Business Wire)-September 28, 2009 - Thommen Medical, a leading Swiss company in the area of the oral implantology, will officially launch the latest products in the evolution of implant surface technology, APLIQUIQ and INICELL, at the 2009 AAOMS Meeting in Toronto, Canada. APLIQUIQ and...

41 - Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin)

WHITEHOUSE STATION, N.J.-(Business Wire)-September 25, 2009 - Merck & Co., Inc., issued the following statement today in response to the U.S. Food and Drug Administration's (FDA's) update on JANUVIA (sitagliptin) and JANUMET (sitagliptin/metformin). "Merck has thoroughly reviewed the safety data...

42 - Quintiles and Allergan Announce Co-Promotion for Sanctura XR®

RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 25, 2009 - Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for...

43 - Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma

CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data...

44 - Advaxis Secures $5.0 Million Investment

NORTH BRUNSWICK, N.J.-(Business Wire)-September 25, 2009 - Advaxis, Inc. (OTCBB: ADXS), has entered into a definitive agreement for a $5 million investment commitment (the “Investment”) with an investment fund (the “Investor”). “This financing, combined with our current debt offering, will...

45 - EnzymeRx Announces Its IND for Uricase-PEG 20 Becomes Effective

PARAMUS, N.J.-(Business Wire)-September 25, 2009 - EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, today announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become...

46 - Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801

MIRAMAR, Fla.-(Business Wire)-September 25, 2009 - Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its...

47 - Diabetes Foot Specialists Say Cost-Effective Wound Therapy Underused Due to Healthcare Reimbursement Incentives

-(Business Wire)-September 25, 2009 - WHAT: Every 30 seconds, across the globe an individual loses a limb due to poor diabetes management. In the U.S., diabetes affects nearly 24 million people. When poorly controlled, diabetes results in nerve damage and poor circulation to the legs and feet...

48 - Dyax Corp. to Present at the JMP Securities Healthcare Focus Conference

CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Fourth Annual JMP Securities Healthcare Focus...

49 - Reverse Medical Corporation Receives FDA IDE Clinical Study Approval for the ReStoreTM Microcatheter

IRVINE, Calif.-(Business Wire)-September 24, 2009 - Reverse Medical Corporation announced today that it has received US Food and Drug Administration (FDA) conditional approval to begin a neurothrombectomy IDE study for its ReStore™ Microcatheter at twenty US centers. The study is planned to...

50 - NEVO™ Sirolimus-Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months Than Taxus® Liberte® Stent

SAN FRANCISCO-(Business Wire)-September 24, 2009 - At six months, patients receiving the NEVO™ Sirolimus-eluting Coronary Stent reported significantly less chest pain (also known as angina) than those receiving the Taxus® Liberte® Stent. Patients also reported improvements in their overall...

51 - Tryton Medical, Inc. Broadcasts Successful Live Case Using Company’s Side-Branch Stent™ to Definitively Treat Bifurcation Lesions at TCT 2009

DURHAM, N.C. & SAN FRANCISCO-(Business Wire)-September 24, 2009 - Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today the transmission of a live satellite feed of a clinical case performed in the United Kingdom to an...

52 - Advaxis Cures Late Form 10-Q Filing

NORTH BRUNSWICK, N.J.-(Business Wire)-September 24, 2009 - Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, announced today that the Company's ticker symbol has been temporarily changed to ADXSE denoting untimely filing of the Company’s July 31, 2009...

53 - Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting

CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that sustained virologic response (SVR) data from Study C208, which evaluated twice-daily dosing of Vertex’s investigational hepatitis C virus (HCV) protease inhibitor...

54 - Imprime PGG® Named a Top 10 Oncology Drug Candidate for Partnering

EAGAN, Minn.-(Business Wire)-September 24, 2009 - Biothera, a privately held biotechnology company, announced today that its lead drug candidate, Imprime PGG®, has been named one of the Top 10 Most Interesting Oncology Projects Available for Partnering by Windhover Information Inc. in conjunction...

55 - Inhibitex Regains Compliance with NASDAQ Listing Requirements

ATLANTA-(Business Wire)-September 24, 2009 - Inhibitex, Inc. (Nasdaq: INHX) (the “Company”), a biopharmaceutical company focused on developing products to treat serious infectious diseases, announced today that it has received notice from The NASDAQ Stock Market ("Nasdaq") stating that, as the...

56 - RegeneRx Biopharmaceuticals to Present Several Papers at Second International Symposium on Thymosins in Health and Disease

BETHESDA, Md.-(Business Wire)-September 24, 2009 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (www.regenerx.com) announced today that it will participate in the Second International Symposium on Thymosins in Health and Disease. This conference will take place from September 30, through...

57 - MEDICREA PASS® LP De-Rotation Connector on the U.S. Market

LYON, France-(Business Wire)-September 24, 2009 - MEDICREA® (Paris:ALMED) announced today the launch of the PASS® LP De-Rotation connector on the U.S. market, and the preparation of a U.S. prospective multicenter clinical study analyzing the 3D correction of adolescent idiopathic scoliosis by...

58 - PHT Corporation Promotes Dwight Cooper to Vice President of Client Services

BOSTON-(Business Wire)-September 24, 2009 - PHT Corporation, the leading provider of ePRO solutions used in pharmaceutical and biotechnology clinical trials worldwide, today announced the promotion of company executive Dwight Cooper to Vice President of Client Services. Mr. Cooper has over 15...

59 - Prime-Boost Vaccine Study Shows Modest Effect in Preventing HIV

SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 24, 2009 - Global Solutions for Infectious Diseases (“GSID”) announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The...

60 - Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia

CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Genzyme Corporation (Nasdaq: GENZ) announced today that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL...

61 - Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation

BERLIN-(Business Wire)-September 24, 2009 - Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC...

62 - BSD Medical Corporation Files $50 Million Shelf Registration

SALT LAKE CITY-(Business Wire)-September 24, 2009 - BSD Medical Corporation (NASDAQ:BSDM) (www.BSDMedical.com) today announced the filing of a shelf registration statement on Form S-3 with the Securities and Exchange Commission. The shelf registration statement, when declared effective by the...

63 - Teva Provides Update on Generic Evista® Litigation

JERUSALEM-(Business Wire)-September 24, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA’s Orange Book for Eli Lilly’s Evista...

64 - IAVI Statement on Results of Phase III ALVAC-AIDSVAX Trial in Thailand

NEW YORK-(Business Wire)-September 24, 2009 - The International AIDS Vaccine Initiative (IAVI) greeted with excitement today’s announcement by the U.S. Military HIV Research Program and the Thai Ministry of Public Health that, according to an initial analysis, a prime-boost combination of two AIDS...

65 - Results of ADAGIO Study with AZILECT® in Parkinson’s Disease Published in New England Journal of Medicine

JERUSALEM-(Business Wire)-September 23, 2009 - Results from the ADAGIO trial, published online today in The New England Journal of Medicine, demonstrated that Parkinson’s disease patients receiving AZILECT® (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior...

66 - Cambridge Heart Announces New Research and Development Initiative

TEWKSBURY, Mass.-(Business Wire)-September 23, 2009 - Cambridge Heart, Inc. (OTCBB-CAMH) announced today that it intends to pursue research and development efforts on a new application derived from its core Microvolt T-Wave Alternans (MTWA) technology. The Company has gathered data, which although...

67 - FAME Trial Two-Year Follow-Up Results Demonstrate Continued Reduction in Risk of Death or Heart Attack When Physicians Use St. Jude Medical Fractional Flow Reserve Technology Prior to Implanting Coronary Stents

ST. PAUL, Minn.-(Business Wire)-September 23, 2009 - St. Jude Medical, Inc. (NYSE:STJ) today announced that the two-year results from the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial demonstrated the durability of the improved outcomes noted at...

68 - PsoriasisDX and HairDX To Present “Pharmacogenomics In Dermatology And Cosmetics” During EADV Congress

BERLIN & IRVINE, Calif.-(Business Wire)-September 23, 2009 - A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the...

69 - BioPharm America™ 2009 in San Francisco Sets New Benchmark for Partnering Productivity in the US

CARLSBAD, Calif. & SAN FRANCISCO-(Business Wire)-September 23, 2009 - Over 700 leaders from the biotechnology and pharmaceutical industry gathered last week for the 2nd annual BioPharm America™ partnering conference, which saw delegates from 665 companies engage in 1579 one-to-one partnering...

70 - Two Top Heart Surgeons Join Endovalve, Inc., Scientific Advisory Board

PRINCETON, N.J.-(Business Wire)-September 23, 2009 - Endovalve, Inc., a cardiovascular device company developing the first valve-replacement system to treat mitral regurgitation, has added two top heart surgeons to its scientific advisory board (SAB), bringing the number of board members to seven...

71 - pSivida Anounces New Iluvien® Pilot Study in Patients with Macular Edema Secondary to Retinal Vein Occlusion

WATERTOWN, Mass.-(Business Wire)-September 23, 2009 - pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FWB:PV3), a leading drug delivery company that has developed two of the only three products approved by the FDA for the long term, sustained release delivery of drug to treat chronic back of the eye disease...

72 - KIKA Clinical Solutions Announces Veracity™ 3.7, New Version of Advanced EDC Solution for Clinical Trial Management

BOSTON & PARIS-(Business Wire)-September 23, 2009 - KIKA Clinical Solutions, the leading provider of advanced EDC solutions for clinical trials, continues leading the industry in providing solutions that go well beyond traditional EDC with the release of Veracity™ 3.7. Veracity™ is a...

73 - First-Ever Controlled Pharmacological Study of ADHD in College Students Launched

BETHLEHEM, Pa.-(Business Wire)-September 23, 2009 - In an effort to help one of the most under studied groups of sufferers of attention deficit hyperactivity disorder (ADHD), researchers at University of Rhode Island and Lehigh University have kicked off the first-ever controlled pharmacological...

74 - Abiomed Reports Results from Academic Medical Center’s Three-Year Follow-up of MACH II Trial

DANVERS, Mass.-(Business Wire)-September 23, 2009 - Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new clinical data from Academic Medical Center’s (AMC) three-year follow-up results from patients in the Impella 2.5 arm of the MACH II...

75 - Merck and QIAGEN Collaborate to Accelerate Access to Cervical Cancer Vaccination and Screening in Developing Countries

NEW YORK-(Business Wire)-September 23, 2009 - Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world. This initiative is the first time a vaccine...

76 - Genzyme Provides Update on Cerezyme and Fabrazyme Supply

CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these...

77 - Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress

BERLIN-(Business Wire)-September 23, 2009 - According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, ERBITUX® (cetuximab), when added to FOLFIRI, was shown to increase median overall survival to 19.9 months in an intent-to-treat (ITT) population of first-line metastatic...

78 - Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye

JERSEY CITY, N.J.-(Business Wire)-September 23, 2009 - Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class...

79 - Philips and Bruker BioSpin Sign Memorandum of Understanding to Bring New Imaging Technology to the Preclinical Market

MONTREAL-(Business Wire)-September 23, 2009 - At the 2009 World Molecular Imaging Congress (WMIC) in Montreal, Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Bruker BioSpin, a division of Bruker Corporation (NASDAQ: BRKR), today announced that they have signed a memorandum of understanding...

80 - Philips and Celsion Advance Development of ThermoDox® and MR-Guided HIFU

ANDOVER, Mass. & COLUMBIA, Md.-(Business Wire)-September 23, 2009 - Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox® in combination with MR-HIFU (Magnetic Resonance guided High...

81 - Elixir Medical Corporation Announces Positive First-In-Man Results for Three Drug Eluting Coronary Stent Systems with Durable and Bioabsorbable Polymers

SUNNYVALE, Calif. & SAN FRANCISCO-(Business Wire)-September 23, 2009 - Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today positive results from three multicenter first-in-man studies of NovolimusTM...

82 - Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease

HAIFA, Israel-(Business Wire)-September 23, 2009 - Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment...

83 - Humedica’s Next-Generation Clinical Informatics Platform Offers Unparalleled Insight across the Health Care Continuum

BOSTON-(Business Wire)-September 23, 2009 - Humedica, a next-generation health care informatics company, today announced the company’s official launch, along with the previous completion of its $30 million round of venture capital and the roll-out of its ground-breaking clinical analytics...

84 - Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva® and Avastin® in Non-Small Cell Lung Cancer

CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small...

85 - Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients

BERLIN, Germany & BERKELEY, Calif.-(Business Wire)-September 23, 2009 - Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032...

86 - BioTime, Inc. to Form Asian Subsidiary

BEIJING & ALAMEDA, Calif.-(Business Wire)-September 23, 2009 - BioTime, Inc. (OTCBB:BTIM) announced today that it will organize a new subsidiary, BioTime Asia, Limited, for the purpose of clinically developing and marketing therapeutic stem cell products in the People’s Republic of China...

87 - BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 22, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that they have determined the final exchange ratio as 0.1828 in connection with the previously announced...

88 - Transoma Medical Enrolls First Patient in Clinical Study Comparing Use of External Recorders with Implantable Monitors to Track Recurrence of Atrial Fibrillation

ST. PAUL, Minn.-(Business Wire)-September 22, 2009 - Transoma Medical, Inc., manufacturer of Sleuth AT™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced today the first enrollment and implant in the...

89 - Top 20 Pharma Firms to Hunt for Deals at BIO-Europe 2009

ZURICH & VIENNA-(Business Wire)-September 22, 2009 - In order to seek out new partnering opportunities, the top 20 big pharma companies will be in attendance on November 2–4 in Vienna, Austria for BIO-Europe 2009, the largest dedicated partnering conference in Europe. Teams of scouts from...

90 - Bio-Path Holdings, Inc. Announces Plans to Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center

HOUSTON-(Business Wire)-September 22, 2009 - Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to...

91 - MagForce Nanotechnologies Completes Patient Recruitment for Pivotal Glioblastoma Study

BERLIN-(Business Wire)-September 22, 2009 - MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy. The results of this...

92 - United BioSource Consolidates Leadership in Pharmaceutical Risk Management

BETHESDA, Md.-(Business Wire)-September 22, 2009 - United BioSource Corporation (UBC) today announced the acquisition of Gigamoto Technology Partners, Inc. (Gigamoto), a Pennsylvania-based software development company providing leading-edge technology solutions in support of drug safety and risk...

93 - Advanced Cell Completing Pre-Clinical Activities in Preparation for IND Filing

WORCESTER, Mass.-(Business Wire)-September 22, 2009 - Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC) provided an update on pre-clinical activities in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for...

94 - Stentys Discloses Results for World’s First Clinical Study to Treat Acute Myocardial Infarction (AMI) with a Self-Expanding Stent

PRINCETON, N.J. & PARIS-(Business Wire)-September 22, 2009 - Medical device pioneer Stentys announced today the results on 20 patients participating in the Company’s ‘APPOSITION I’ clinical study—the world’s first to treat patients with acute myocardial infarction (AMI) via a...

95 - Cardiovascular Systems Reports Two-Year Data Showing Durable Outcomes in Patients Treated with Diamondback 360° Pad System

ST. PAUL, Minn. & SAN FRANCISCO-(Business Wire)-September 22, 2009 - Two-year follow-up of patients in the first-ever prospective, multi-center clinical trial evaluating a plaque removal product show promising results after treatment with the Diamondback 360® PAD System, a minimally invasive...

96 - New Clinical Data on Medtronic Transcatheter Heart Valves Featured in More Than 25 Presentations at TCT 2009

MINNEAPOLIS-(Business Wire)-September 22, 2009 - With the promise of percutaneous treatments for patients with diseased heart valves growing, Medtronic, Inc. (NYSE: MDT), announced today that more presentations than ever before – at least 25 – on the company’s portfolio of unique transcatheter...

97 - Imaging Diagnostic Systems Sells CTLM System in Malaysia

FORT LAUDERDALE, Fla.-(Business Wire)-September 22, 2009 - Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast imaging systems, announced today the sale of another CT Laser Mammography system in Asia. The system, which was sold to and installed at the Katherine Women’s...

98 - PRA International Names Phase Forward’s OutcomeLogix™ as Preferred Late Phase Solution

WALTHAM, Mass.-(Business Wire)-September 22, 2009 - Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that PRA International has named Phase Forward’s OutcomeLogix™ as its preferred late phase solution provider...

99 - PHT’s LogPad ePRO System used by Jazz Pharmaceuticals

BOSTON-(Business Wire)-September 22, 2009 - PHT Corporation announced that Jazz Pharmaceuticals (Nasdaq: JAZZ) has used PHT’s LogPad™ System to collect electronic patient reported outcomes (ePRO) in its recently completed clinical trial. Jazz Pharmaceuticals’ recent project builds on the...

100 - Curis to Present at Maxim Group Growth Conference 2009

CAMBRIDGE, Mass.-(Business Wire)-September 22, 2009 - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Maxim Group Growth Conference...

101 - BSD Medical Reports News Briefing at Europe’s Largest Cancer Congress: Hyperthermia and Chemotherapy Treatment Prolongs Survival of Sarcoma Cancer Patients

SALT LAKE CITY-(Business Wire)-September 22, 2009 - BSD Medical Corporation (NASDAQ:BSDM) reports that significant and “medical practice changing” clinical study results were the subject of a news briefing at Europe’s largest cancer congress, ECCO15 – ESMO34, which is being held September 20...

102 - Opexa to Present at the Wall Street Analyst Forum 20th Annual Analyst Conference

THE WOODLANDS, Texas-(Business Wire)-September 22, 2009 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s president and chief executive officer, will deliver a...

103 - Helicos Presents at Cold Spring Harbor Laboratories Personal Genomes and CHI Next Generation Sequencing Meetings

CAMBRIDGE, Mass.-(Business Wire)-September 22, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS) provided updates on recent scientific findings and progress on Helicos’s technology initiatives. Speaking at the Personal Genomes conference in Cold Spring Harbor, NY, and the CHI Next Generation...

104 - Protalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug

CARMIEL, Israel-(Business Wire)-September 22, 2009 - Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), reported today preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel™). Produced using the Company’s proprietary ProCellEx™ technology, pr-antiTNF is a plant cell...

105 - Celera and Medco Enter Research Collaboration to Evaluate Effect of KIF6 Testing on Compliance with Statin Therapy in Patients with Cardiovascular Disease

ALAMEDA, Calif. & FRANKLIN LAKES, N.J.-(Business Wire)-September 22, 2009 - Celera Corporation (NASDAQ:CRA) and Medco Health Solutions, Inc. (NYSE:MHS), today announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6 increases...

106 - Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer’s AROMASIN® (Exemestane Tablets)

BERLIN-(Business Wire)-September 22, 2009 - Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the...

107 - Dynavax Announces HEPLISAVTM Data to Be Presented at IDSA Medical Conference

BERKELEY, Calif.-(Business Wire)-September 22, 2009 - Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that an abstract with chronic kidney disease patient data for HEPLISAVTM, an investigational adult hepatitis B vaccine, will be presented at the 47th Annual Meeting of the...

108 - New England IRB Announces Results of FDA Audit

WELLESLEY, Mass.-(Business Wire)-September 21, 2009 - New England IRB is pleased to announce that FDA has sent written notification that the results of their audit conducted in November 2008 indicate no significant findings. No further action is required. In the current climate of increased...

109 - Adolor Acquires Rights to Clinical-Stage Product Candidate from Eli Lilly and Company

EXTON, Pa.-(Business Wire)-September 21, 2009 - Adolor Corporation (NasdaqGM:ADLR) today announced that it has acquired from Eli Lilly and Company (“Lilly”) the exclusive worldwide rights to OpRA III, a clinical-stage product candidate. OpRA III is a potent opioid receptor antagonist, with...

110 - Burnham Appoints Michael R. Jackson, Ph.D., Vice President for Drug Discovery & Development

LA JOLLA, Calif.-(Business Wire)-September 21, 2009 - Burnham Institute for Medical Research (Burnham) has appointed Michael R. Jackson, Ph.D., to the newly created position of Vice President for Drug Discovery and Development. In this role, Dr. Jackson will oversee the chemical biology and drug...

111 - Mentor Capital, Inc. Completes 2nd Year Audit for OTCBB Move; Reporting $0.16 Per Share in Basic Earnings

SAN DIEGO-(Business Wire)-September 21, 2009 - Mentor Capital, Inc. (Pink Sheets:MNTR) completed its FY 2008 audit in preparation for filing a self-registration statement with the SEC and applying to move from the Pink Sheets to begin being quoted on the Over-the-Counter Bulletin Board system. The...

112 - Medtronic’s Resolute® Drug-Eluting Stent Maintains Strong, Sustained Efficacy and Safety in Long-Term Follow-up

SAN FRANCISCO-(Business Wire)-September 21, 2009 - New clinical data released today at a major meeting of interventional cardiologists show strong and sustained efficacy and safety of the Resolute® Zotarolimus-Eluting Coronary Stent from Medtronic, Inc. (NYSE: MDT) in long-term patient follow-up...

113 - ENDEAVOR® Stent Reduced Risk of Heart Attack/Cardiac Death by 48% at Three Years Compared to Taxus® Stent in Large Study

SAN FRANCISCO-(Business Wire)-September 21, 2009 - Anticipating a change in the practice of interventional cardiology, Medtronic, Inc. (NYSE: MDT), announced today that the latest findings from the ENDEAVOR IV clinical trial – a large study comparing two drug-eluting coronary stents head-to-head...

114 - In a Tough Economy, Bioscience Research, LLC Helps Eligible Westchester County Residents Access Depression Care at no Cost

MOUNT KISCO, N.Y.-(Business Wire)-September 21, 2009 - Psychiatrists at Bioscience Research, LLC, understand the mental health burden that can accompany unemployment and the day-to-day stress of looking for a new job or worrying about losing an existing job. In response to the area’s increased...

115 - Vitae Initiates Phase 1 Trial of Novel Renin Inhibitor

FORT WASHINGTON, Pa.-(Business Wire)-September 21, 2009 - Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999. VTP-27999 is a novel, proprietary renin inhibitor...

116 - Dicerna Pharmaceuticals to Present at 2009 Biologics Drug Delivery & Beyond Conference

WATERTOWN, Mass.-(Business Wire)-September 21, 2009 - Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and dicer substrate RNAi molecules, today announced that Sujit K. Basu...

117 - Biogen Idec Commences Tender Offer for Facet Biotech

CAMBRIDGE, Mass.-(Business Wire)-September 21, 2009 - Biogen Idec Inc. (NASDAQ:BIIB) announced today that FBC Acquisition Corp., its wholly owned subsidiary, has commenced a tender offer to acquire all of the outstanding shares of Facet Biotech Corporation (NASDAQ:FACT) for $14.50 per share in cash...

118 - Rexahn Pharmaceuticals and Teva Pharmaceutical Industries Close on a License Agreement

ROCKVILLE, Md.-(Business Wire)-September 21, 2009 - Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced...

119 - Maxygen Announces Consummation of Joint Venture Transaction With Astellas

REDWOOD CITY, Calif.-(Business Wire)-September 21, 2009 - Maxygen, Inc. (Nasdaq:MAXY) today announced the consummation of the transactions contemplated by the previously announced joint venture agreement between Maxygen and Astellas Pharma Inc. Under the joint venture transaction, which closed on...

120 - Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis

WILMINGTON, Del.-(Business Wire)-September 21, 2009 - Incyte Corporation (Nasdaq:INCY) announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis. These results were obtained from a multi-center three-month Phase IIb trial...

121 - PerkinElmer Launches Columbus™ 2.0 High Content Screening Platform for High-Volume Image Data Management and Analysis

BOSTON-(Business Wire)-September 21, 2009 - At the High Content Analysis East conference in Boston, PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the launch of the Columbus™ 2.0 platform, its flagship high content...

122 - Enzo Biochem and National Institutes of Health to Cooperate in Development of Enzo’s Novel Therapeutic Candidate for Treatment of Autoimmune Uveitis

NEW YORK-(Business Wire)-September 21, 2009 - Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel...

123 - ARIAD Announces Clinical Data from Phase 1 Study of Its Investigational mTOR Inhibitor, Ridaforolimus, in Combination with Bevacizumab

CAMBRIDGE, Mass.-(Business Wire)-September 21, 2009 - ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with...

124 - Provectus Completes Treatment of All Patients in Phase 2 Trial of PV-10 for Metastatic Melanoma

KNOXVILLE, Tenn.-(Business Wire)-September 21, 2009 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical...

125 - Data Safety Monitoring Board Recommends Continuation of Celsion’s Phase III ThermoDox® Study for Primary Liver Cancer

COLUMBIA, Md.-(Business Wire)-September 21, 2009 - Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board (“DSMB”) has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox® Phase III clinical trial for primary liver cancer...

126 - National Institute of Allergy and Infectious Diseases to Give Update On NIAID-Supported Clinical Trials of 2009 H1N1 Influenza Vaccines in Children Six Months to 17 Years of Age

-(Business Wire)-September 21, 2009 - HHS Media Advisory: WHAT: Anthony S. Fauci, M.D., Director of the National Institute of Allergy and Infectious Diseases, will give an update on NIAID-supported clinical trials of 2009 H1N1 influenza vaccines in children six months to 17 years of age.   Jesse...

127 - Semafore Retains Management Consulting Firm; Names Principal to Key Management Position

INDIANAPOLIS-(Business Wire)-September 21, 2009 - Semafore Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other...

128 - Labor Becker-Olgemoeller Selects Bruker´s MALDI Biotyper as an Integrated Multi-Workstation Solution for Microbial Identification

GÖTTINGEN, Germany-(Business Wire)-September 21, 2009 - At the 61st Annual Meeting of the German Society for Hygiene and Microbiology, Bruker Daltonics announces that Labor Becker-Olgemöller in Munich has installed the Bruker MALDI Biotyper as their next-generation, rapid molecular microbial...

129 - Quidel Issues Clarification Regarding Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Reactivity Information to the QuickVue Influenza A+B Test Package Insert

SAN DIEGO-(Business Wire)-September 18, 2009 - Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, issues clarification regarding the Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert. A news wire agency...

130 - Commonwealth Biotechnologies, Inc. Receives NASDAQ Notification Regarding Bid Price; Grace Period Granted Through March 15, 2010

RICHMOND, Va.-(Business Wire)-September 18, 2009 - Commonwealth Biotechnologies, Inc. (“CBI” or “Company”)) (NASDAQ Capital Market:CBTE) today announced that on September 15, 2009, CBI received a letter from The NASDAQ Stock Market indicating that the bid price of the Company’s common...

131 - PHT and Lionbridge Present Webinar on Strategies for Conducting Successful Clinical Trials in Emerging Markets

BOSTON & WALTHAM, Mass.-(Business Wire)-September 18, 2009 - PHT Corporation and Lionbridge Technologies, Inc. (NASDAQ:LIOX) are sponsoring a webinar to reveal the crucial elements required to avoid operational complexities and financial risk when conducting clinical trials in emerging...

132 - Metabasis Therapeutics Receives Notice of Noncompliance with Nasdaq Listing Requirements

SAN DIEGO-(Business Wire)-September 18, 2009 - Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that based upon the closing...

133 - KCI Sponsors Georgetown Diabetic Limb Salvage Conference Symposium Featuring Top Limb Preservation Experts

SAN ANTONIO-(Business Wire)-September 18, 2009 - Kinetic Concepts, Inc. (KCI) will sponsor a CME-accredited panel discussion, “The Role of NPWT in the Team Approach to Limb Salvage: Case Studies,” at the 3rd Annual Georgetown Diabetic Limb Salvage conference September 24-26. At the symposium...

134 - NovoStent Announces Completion of Enrollment in SAMBA Femoropopliteal Trial

MOUNTAIN VIEW, Calif.-(Business Wire)-September 18, 2009 - NovoStent Corporation, a privately held medical device company, today announced the completion of enrollment earlier this summer in the company’s European clinical trial evaluating the use of its SAMBATM Stent and Delivery System in the...

135 - Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents

NEW YORK-(Business Wire)-September 18, 2009 - Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer,1 updated study results from a Phase 3 study of Sutent® (sunitinib malate) in...

136 - Hyperion Therapeutics to Present at UBS 2009 Global Life Sciences Conference

SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 18, 2009 - Hyperion Therapeutics, Inc. today announced that Donald Santel, Chief Executive Officer, will present at the UBS 2009 Global Life Sciences Conference on Wednesday September 23, 2009 at 4:30 pm ET. The conference will be held at the...

137 - FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE® (bortezomib) for Injection

CAMBRIDGE, Mass.-(Business Wire)-September 18, 2009 - Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall...

138 - BSD Medical Corporation Reports FDA Review of BSD-2000 Hyperthermia System Continues

SALT LAKE CITY-(Business Wire)-September 18, 2009 - BSD Medical Corporation (NASDAQ: BSDM) (www.bsdmedical.com) reported today that the U.S. Food and Drug Administration (FDA) continues its review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s...

139 - Pilot Study Shows That Pico-Tesla’s Proprietary Magnetic (Magneceutical™) Therapy Demonstrated “Significant Improvement over Placebo” in Reducing Parkinson’s Disease Symptoms, Which Persisted up to 2 Months Post-Treatment with No Side Effects

LITTLETON, Colo.-(Business Wire)-September 18, 2009 - Pico-Tesla, The Magneceutical™ Therapy Company, announced today that a pilot study of its proprietary magnetic (Magneceutical™) therapy for Parkinson’s disease patients “demonstrated significant improvement over placebo after 8 weeks...

140 - Dr. Kevin Krenitsky, President of Enzo Clinical Labs, to Present At 27th Annual Lab Institute

NEW YORK-(Business Wire)-September 18, 2009 - Enzo Biochem, Inc. (NYSE:ENZ) announced today that Kevin Krenitsky, MD, President of Enzo Clinical Labs, will present at the 27th Annual Lab Institute ’09, sponsored by Washington G2 Reports, on September 23, 2009 in Arlington, Virginia. Dr...

141 - Array BioPharma Enters into Equity Distribution Agreement

BOULDER, Colo.-(Business Wire)-September 18, 2009 - Array BioPharma Inc. (Nasdaq: ARRY) today announced it had entered into an Equity Distribution Agreement with Piper Jaffray & Co. The Equity Distribution Agreement provides that the Company may offer and sell shares of its common stock, par...

142 - Resolvyx Granted U.S. Patent for the First Resolvin Therapeutic to Enter Human Trials

BEDFORD, Mass.-(Business Wire)-September 18, 2009 - Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin...

143 - Clinical Data, Inc. Announces Pharmaceutical Industry Leader Joins the Board of Directors

NEWTON, Mass.-(Business Wire)-September 18, 2009 - Clinical Data, Inc. (NASDAQ: CLDA) today announced the election of Scott Tarriff to the Board of Directors. Mr. Tarriff has 25 years of pharmaceutical experience, including serving as President and Chief Executive Officer of Par Pharmaceutical...

144 - Pancreatic and Colorectal Cancer Novel Antibody Developed from a Vaccine to Begin Phase I Trial

GREAT NECK, N.Y.-(Business Wire)-September 17, 2009 - Neogenix Oncology, Inc. (Neogenix) announced today that NPC-1C, the company’s first IND (Investigational New Drug Application) was granted permission by the Food and Drug Administration (FDA) for the company to begin a Phase I trial. NPC-1C...

145 - Seattle Genetics to Present at UBS Global Life Sciences Conference

BOTHELL, Wash.-(Business Wire)-September 17, 2009 - Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2009 UBS Global Life Sciences Conference on Tuesday, September 22, 2009, at 2:00 p.m. Eastern Time. The...

146 - The Bioscience Conference That Thinks Globally

COLUMBUS, Ohio-(Business Wire)-September 17, 2009 - On October 1 the 2009 BioOhio Annual Conference, “BioGPS: Global Positioning for Success,” will focus on the globalization of bioscience and the inherent growth opportunities for Ohio organizations. Conference topics will range from exporting...

147 - Hythiam Raises Approximately $7 Million in Registered Direct Offering

LOS ANGELES-(Business Wire)-September 17, 2009 - Hythiam, Inc. (NASDAQ:HYTM) announced today that it has entered into definitive agreements to sell 9,333,334 shares of its common stock at a price per share of $.75 to institutional investors pursuant to a registered direct offering, representing...

148 - Meridian Bioscience Granted Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Analytical Sensitivity Claim to the TRU FLU® Test Package Insert

CINCINNATI-(Business Wire)-September 17, 2009 - Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the company has been granted a Special 510(k) clearance to update the TRU FLU package insert to include analytical sensitivity claims with two strains of 2009 H1N1 virus...

149 - New Essentials Glycemic Health Brand Pasta Launched Using Hi-maize Natural Resistant Starch

BRIDGEWATER, N.J.-(Business Wire)-September 17, 2009 - National Starch Food Innovation today announced the launch of a new Hi-maize-enriched pasta by Racconto, a leading U.S. importer-producer of private label and branded Italian pasta. The all-natural Essentials Glycemic Health pasta line from...

150 - Lantheus Medical Imaging, Inc. Initiates Phase 1 Study Evaluating Safety and Dosimetry of Novel Heart Failure Imaging Agent

N. BILLERICA, Mass.-(Business Wire)-September 17, 2009 - Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging...

151 - EKR Therapeutics to Present at the 2009 UBS Global Life Sciences Conference

BEDMINSTER, N.J.-(Business Wire)-September 17, 2009 - EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing critical-care products for the hospital setting, today announced that Howard Weisman, CEO & President, will present at the UBS Global Life Sciences...

152 - Vascular Surgeons Present Positive Study Results for the GORE PROPATEN® Vascular Graft and Updates to the GORE VIABAHN® Endoprosthesis

FLAGSTAFF, Ariz.-(Business Wire)-September 17, 2009 - W. L. Gore & Associates (Gore) today announced that several physicians recently presented interim data from ongoing GORE PROPATEN® Vascular Graft studies to clinical audiences at the 2009 annual vascular meeting. The conference, the...

153 - Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Hepatic Encephalopathy

SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 17, 2009 - Hyperion Therapeutics, Inc. today announced that its investigational product HPN-100 (glycerol phenylbutyrate) has received orphan product designation from the U.S. Food and Drug Administration for intermittent or chronic treatment...

154 - Seaside Therapeutics Secures $30 Million Financing

CAMBRIDGE, Mass.-(Business Wire)-September 17, 2009 - Seaside Therapeutics LLC today announced that it has secured $30 million in financing from a private, family investment firm which is committed to advancing research in the field of autism and Fragile X Syndrome. The financing will be used to...

155 - Juvaris BioTherapeutics Announces First Close on $25 million Series B Financing

BURLINGAME, Calif.-(Business Wire)-September 17, 2009 - Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed the first close on its Series B equity financing of up to $25 million led by SV Life Sciences...

156 - RiskMetrics Group – ISS Governance Services Recommends Stockholders Vote “FOR” BioSante and Cell Genesys Merger

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 17, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that...

157 - Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference

ROCKVILLE, Md.-(Business Wire)-September 17, 2009 - Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 2009 UBS Global Life Sciences Conference will be webcast and may be accessed at www.hgsi.com. A member of Human Genome Sciences’ senior management team will...

158 - Power3 Medical Products, Inc. Headlines Session at International Molecular Diagnostic Meeting in China

HOUSTON-(Business Wire)-September 17, 2009 - Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf, will deliver an...

159 - RiskMetrics Group – ISS Governance Services Recommends Stockholders Vote “FOR” BioSante and Cell Genesys Merger

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 17, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended...

160 - Positive Phase IIb Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Post-Herpetic Neuralgia

RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.-(Business Wire)-September 17, 2009 - GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for...

161 - Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.-(Business Wire)-September 17, 2009 - Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Biogen Idec (Nasdaq:BIIB), today announced that a Phase III study (PRIMA) showed that patients with follicular...

162 - EBD Group and Defined Health Form an Alliance on Conference Content

CARLSBAD, Calif. & ZURICH, Switzerland & FLORHAM PARK, N.J.-(Business Wire)-September 16, 2009 - EBD Group and Defined Health today announced the formation of an alliance that will help biopharmaceutical firms gain the insights they need to create and execute successful strategy. Under...

163 - Phase Forward to Present at the UBS Global Life Sciences Conference

WALTHAM, Mass.-(Business Wire)-September 16, 2009 - Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its chairman and chief executive officer, Bob Weiler, and senior vice president and chief financial officer, Chris...

164 - Bioheart Inc. Announces Positive Results in the MARVEL Phase II/III Clinical Trial

SUNRISE, Fla.-(Business Wire)-September 16, 2009 - Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine...

165 - Internationally Acclaimed Inventor, Dean Kamen, to Receive Prestigious BioMed SA Palmaz Award for Innovation in Healthcare and the Biosciences

SAN ANTONIO-(Business Wire)-September 16, 2009 - Internationally renowned inventor, entrepreneur and thought leader, Dean Kamen of Manchester, NH, can add another prestigious award to his resume when he accepts BioMed SA’s Julio Palmaz Award for Innovation in Healthcare and the Biosciences. BioMed...

166 - Metabolomics Used to Identify the Mechanism of Action of an Anti-Cancer Drug

RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 16, 2009 - Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at...

167 - Urovalve files patent for new product offering

NEWARK, N.J.-(Business Wire)-September 16, 2009 - Urovalve announced today that the Company has filed a patent to protect its new product offering in development that facilitates insertion of catheters, such as a Foley catheter. The new Urovalve device is novel because it is designed not only to add...

168 - Mentor Capital Cancer Immunotherapy Index Posts Second 20% Plus Monthly Gain Lead by ImmunoCellular Therapeutics

SAN DIEGO-(Business Wire)-September 16, 2009 - The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the...

169 - Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

CAMBRIDGE, Mass.-(Business Wire)-September 16, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement...

170 - Cyntellect Launches Stem Cell Manager™ Powered by LEAP™

SAN DIEGO-(Business Wire)-September 16, 2009 - Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of Stem Cell Manager...

171 - NMT Medical to Accelerate CLOSURE I Data Analysis Timing

BOSTON-(Business Wire)-September 16, 2009 - NMT Medical, Inc. (NASDAQ: NMTI) announced today that, upon recommendation of the CLOSURE I Executive Committee, it will commence data analysis for its landmark patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) clinical trial...

172 - PerkinElmer Purchases GE Healthcare’s Catalog Radiochemicals, SPA Reagents and Cytostar-T Plate Assets

WALTHAM, Mass.-(Business Wire)-September 16, 2009 - PerkinElmer, Inc., a global leader focused on improving the health and safety of people and their environment, today announced that it has purchased the assets of GE Healthcare’s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay...

173 - Johns Hopkins and National Fibromyalgia Association Announce Successful Outcomes from Landmark Educational Initiative

NEW YORK CITY-(Business Wire)-September 16, 2009 - According to The Johns Hopkins University School of Medicine, the Fibromyalgia Circle of Care Initiative has achieved dramatic success in heightening awareness, diagnosis and best practice treatment of fibromyalgia – a complex and chronic pain...

174 - Celsion’s ThermoDox® Study for RCW Breast Cancer Aired on ABC and CBS Affiliate Stations

COLUMBIA, Md.-(Business Wire)-September 16, 2009 - Celsion Corporation (NASDAQ:CLSN) announced today the Company’s DIGNITY clinical trial evaluating the use of ThermoDox® in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial...

175 - CUSTOMER WIN: Phase Forward to Boost Clinical Trial and Drug Safety Services with BMC Software

HOUSTON-(Business Wire)-September 16, 2009 - For many large pharmaceutical and medical device firms, the task of capturing and managing volumes of clinical trial and drug safety data is often outsourced to experts like Phase Forward. To automate the provisioning, deployment and management of servers...

176 - BioClinica™ Acquires Tourtellotte Solutions

NEWTOWN, Pa.-(Business Wire)-September 16, 2009 - BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced that it has acquired privately-held Tourtellotte Solutions, Inc. (Tourtellotte), a leader in software and services for the bio-pharmaceutical industry...

177 - Long Beach Memorial Successfully Implants Cutting-Edge Heart Attack Detection Device

LONG BEACH, Calif.-(Business Wire)-September 15, 2009 - MemorialCare Heart and Vascular Institute at Long Beach Memorial Medical Center (LBMMC) successfully implanted a new, cutting-edge heart attack detection device in two heart attack survivors this morning. With the danger of a second heart...

178 - PPD Opens Global Central Lab in Singapore

WILMINGTON, N.C.-(Business Wire)-September 15, 2009 - PPD, Inc. (Nasdaq: PPDI) today announced it has opened its global central lab facility in Singapore, strengthening its ability to provide biopharmaceutical clients an extensive range of customized laboratory services in Southeast Asia, a...

179 - Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2010 and Reaffirms Fiscal 2009 Guidance

CINCINNATI-(Business Wire)-September 15, 2009 - Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2010 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year...

180 - Quintiles Debuts at # 50 in InformationWeek 500

RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 15, 2009 - Quintiles has been ranked in the 2009 InformationWeek 500, the publication’s annual ranking of the nation’s most innovative users of information technology. Quintiles was ranked 50th in its first time on the list. This distinction...

181 - Breakthrough Genetic Test Helps Doctors Assess Risk Of Developing Psoriatic Arthritis (PsA)

IRVINE, Calif.-(Business Wire)-September 15, 2009 - The first genetic test for Psoriatic arthritis (PsA) is being launched today by PsoriasisDX, LLC, a subsidiary of molecular dermatology research and development innovator PharmaGenoma, Inc. PsA is a progressive irreversible joint disease associated...

182 - THE SAGE GROUP Supports the “Stop P.A.D.” Petition Drive to Expand Medicare Coverage to Test Patients for Peripheral Arterial Disease

ATLANTA-(Business Wire)-September 15, 2009 - In recognition of National P.A.D. Awareness Month, Mary L. Yost, President of THE SAGE GROUP recommends that patients, relatives, and the medical community join the campaign to increase access to a simple noninvasive test to diagnose peripheral arterial...

183 - Nomir Medical Announces Publication of Mechanism-of-Action Data for its Noveon® Dual-Wavelength Device

WALTHAM, Mass.-(Business Wire)-September 15, 2009 - Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today the publication of a scientific paper in the journal Photochemistry and Photobiology that details in vitro and human...

184 - Early Research Shows Cardiac Resynchronization Therapy May Benefit Patients with Ejection Fractions above 35 Percent

MINNEAPOLIS & BOSTON-(Business Wire)-September 15, 2009 - Early findings from a Medtronic, Inc. (NYSE: MDT) sponsored study show heart failure patients with moderate ejection fractions, over 35 percent, may receive comparable benefits from cardiac resynchronization therapy (CRT) as compared to...

185 - RXi Pharmaceuticals’ Self-delivering rxRNAs Demonstrate Superior Drug Properties Compared to Classic RNAi Compounds in Animal Studies

WORCESTER, Mass.-(Business Wire)-September 15, 2009 - RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it will be presenting new in vivo data...

186 - Alvine Pharmaceuticals Raises $21.5 Million Series A Extension

SAN CARLOS, Calif.-(Business Wire)-September 15, 2009 - Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A...

187 - Hyperion Therapeutics Announces First Patient Enrolled in Trial in Children with Urea Cycle Disorders

SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 15, 2009 - Hyperion Therapeutics today announced that the first patient has been enrolled in a clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate) in children ages 6-17 with urea cycle disorders (UCD). The study will...

188 - CPEX Pharmaceuticals to Present at Ninth Annual Diabetes Technology Meeting

EXETER, N.H.-(Business Wire)-September 15, 2009 - CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) (“CPEX”) today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance...

189 - Alnylam and Medtronic Present New Late-Stage Pre-clinical Data on ALN-HTT, an RNAi Therapeutic for the Treatment of Huntington’s Disease

VANCOUVER, B.C.-(Business Wire)-September 15, 2009 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT), the world’s leading developer of medical devices, announced today the presentation of new pre-clinical research findings from...

190 - Acorda Therapeutics Announces Data on Retention Rates and Safety from Two Phase 3 Fampridine-SR Extension Studies

HAWTHORNE, N.Y.-(Business Wire)-September 15, 2009 - Data from two long-term open-label extension studies of Fampridine-SR show that 86.0% of participants remained on therapy after a maximum treatment time of 15 months in study MS-F204EXT, and 69.5% remained on therapy after a maximum treatment time...

191 - KYTHERA Biopharmaceuticals Announces Initiation of First-in-Human Trial for ATX-104 - A Light-Activated Facial Contouring Agent

LOS ANGELES-(Business Wire)-September 15, 2009 - KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has initiated a first-in-human, proof-of-concept study evaluating the safety, tolerability, persistence and histological effects of ATX-104, a light-activated facial contouring...

192 - Cytheris Announces Interim Data from INSPIRE Study Showing Interleukin-7 (CYT107) Induces Dose-Dependent and Sustained Increase of CD4 T Cells in Chronic HIV-Infected Patients

PARIS-(Business Wire)-September 15, 2009 - Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected...

193 - Diagnostic HYBRIDS Announces FDA Clearance of D3® FastPointTM L-DFATM Respiratory Virus Identification Kit

ATHENS, Ohio-(Business Wire)-September 14, 2009 - Diagnostic HYBRIDS, a leading developer of IVD fluorescent staining kits and cell culture products, today announced the U.S. Food and Drug Administration (FDA) (510k) clearance of its D3 FastPointTM L-DFATM Respiratory Virus Identification Kit, which...

194 - NanoBio Presents Key Data on the Use of Nanoemulsions to Treat Burn Wound Infections

ANN ARBOR, Mich.-(Business Wire)-September 14, 2009 - NanoBio Corporation today announced compelling preclinical data for NB-201, a nanoemulsion-based topical lotion for the treatment of burn wounds. In preclinical studies, NB-201 dramatically reduced the severity of burn wound infections as well as...

195 - STEMCELL Technologies Applauds Feeder-Free Derivation of Human Induced Pluripotent Stem Cells

VANCOUVER-(Business Wire)-September 14, 2009 - In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and...

196 - Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting

SAN FRANCISCO-(Business Wire)-September 14, 2009 - Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial...

197 - Altair Therapeutics Reports Successful Phase I Study of Inhaled AIR645

SAN DIEGO & VIENNA-(Business Wire)-September 14, 2009 - Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead...

198 - BioReference Laboratories, Inc to Speak at the UBS Global Life Sciences Conference

ELMWOOD PARK, N.J.-(Business Wire)-September 14, 2009 - BioReference Laboratories, Inc (NASDAQ:BRLI) announced today that Marc D. Grodman M.D., President and Chief Executive Officer, is scheduled to speak at the 2009 UBS Global Life Sciences Conference on Monday, September 21, 2009, at The Grand...

199 - PolyMedix to Make Three Presentations of Antibiotic Data at the 49Th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

RADNOR, Pa.-(Business Wire)-September 14, 2009 - PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will make three presentations of clinical and...

200 - CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia

LOS ANGELES-(Business Wire)-September 14, 2009 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced the initiation of a dose escalation study with its oncology drug candidate tamibarotene combined...

Search Our News Using Google Search

Can't find what you want? Try using Google:

	Enter your search terms Submit search form
	Web www.digital50.com

	Subscribe to our RSS feeds and get press releases delivered daily
	Subscribe to Business Press Releases in up to 210 Industries
	Add the DiGiTAL50 Search to your Site, FREE!